Pavmed Inc. · NASDAQ:PAVM
Pavmed — Investor Presentation (November 2016)
31 slides from Pavmed's investor presentation, Nov 22, 2016
Slide 1: Corporate Presentation Fall 2016
TM NASDAQ: PAVM CORPORATE PRESENTATION Fall 2016 1
Slide 2: Disclaimers
Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but
Slide 3: Innovative multi-product medical device company
Innovative multi-product medical device company… …employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. 3
Slide 4: Investment Highlights
Investment Highlights Unique, proven business model focused on capital efficiency and speed to market Deep, expanding pipeline of innovative products across a broad spectrum of clinical conditions with clear paths to near-term commercialization Attractive market opportunities for lead products total
Slide 5: Leadership team with strong record of value creation
Leadership team with strong record of value creation LISHAN MICHAEL BRIAN AKLOG, MD GLENNON DEGUZMAN, MD CHAIRMAN & CEO VICE CHAIRMAN CHIEF MEDICAL OFFICER A.B. Physics, magna B.A.,Business B.S.Biology cum laude Administration Phi Beta Kappa M.D., cum laude Endoscopy and M.D. Surgical Instrument Gen
Slide 6: Lead products provide near-term value creation opportunities
Lead products provide near-term value creation opportunities PortIO CarpX Implantable Vascular Access Device Percutaneous Carpal Tunnel Device NextCath DisappEAR Self-Anchoring Short-Term Catheters Resorbable Antibiotic-Eluting Ear Tubes NextFlo Caldus Disposable Tissue Ablation Devices Highly Accur
Slide 7: The PAVmed Business Model
The PAVmed Business Model SK PAVmed
Slide 8: Proven record of capital efficiency and speed to market
Proven record of capital efficiency and speed to market TIME AND CAPITAL TO FDA CLEARANCE PAVmed Model 23 months Typical Company 60months 0 12 24 36 48 60 Months PAVmed Model $3 million Typical Company $31 million $0 $10,000,000 $20,000,000 $30,000,000 Dollars (*)Typical Company data from Markower,
Slide 9: Commercial opportunity drives project selection criteria
Commercial opportunity drives project selection criteria Reimbursement Profile High Margin Product Technology Profile Commercial Opportunity Unmet Clinical Need Attractive Market Regulatory Profile 9
Slide 10: Key business processes deliver capital and time efficiency
Key business processes deliver capital and time efficiency Outsourced Parallel Regulatory Best-in-class Development Strategy Process Experts Processes Capital Speed To Efficiency Market Light Flexible Infrastructure Commercialization Low Fixed Costs Strategy 10
Slide 11: Multi-product strategy enhances value creation
Multi-product strategy enhances value creation Economies Of Risk Mitigation Scale Flexible, Dynamic Non-binary Allocation Of Success Resources Enhanced Value Creation 11
Slide 12: Flexible commercialization strategy accelerates value creation
Flexible commercialization strategy accelerates value creation Remain Opportunistic Initiate Accelerate To Maximize Commercialization Revenue Growth Value Creation INDEPENDENT CORPORATE CORPORATE REGULATORY DISTRIBUTOR PARTNER PARTNER CLEARANCE NETWORK Sales and Distribution Licensing agreement Call
Slide 13: Lead Product Development Pipeline
Lead Product Development Pipeline 13
Slide 14: Lead products provide near-term value creation opportunities
Lead products provide near-term value creation opportunities COMMERCIALIZATION REGULATORY PRODUCT ADDRESSABLE MARKET INITIAL TARGET PATH CHANNEL DATE PortIO Independent Q2 Long-term Implantable Vascular Access Ports $500M 510(k) Distributors 2017 Vascular Access Devices CarpX Percutaneous Treatment
Slide 15: Vascular Access Devices
Vascular Access Devices CLINICAL OVERVIEW MARKET OPPORTUNITY Long-term Short-term ~7 million central vascular access devices (US) Weekto Months Days to Week ~400-500,000 implantable ports (US) Chemotherapy, antibiotics, intravenous nutrition, Acute in-hospitalinfusions, biologics and other medicatio
Slide 16: PortIO The PAVmed Solution
PortIO The PAVmed Solution INTRAOSSEOUS VASCULAR ACCESS IMPLANTABLE INTRAOSSEOUS PORT Infusion directly into the bone marrow cavity NO INTRAVASCULAR COMPONENT Rapid, direct drainage into central venous circulation via Subcutaneous, implantable intraosseous vascular access nutrient/emissary veins Sel
Slide 17: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome CLINICAL OVERVIEW MARKET OPPORTUNITY Estimated prevalence 3-8% of adults = 5 million Estimated $1 billion market Not considering 1.4M patients/year who choose not to >3M office visits per year undergo surgery but might consider percutaneous approach Over 600,000 U.S. procedure
Slide 18: CarpX The PAVmed Solution
CarpX The PAVmed Solution PERCUTANEOUS DEVICETOTREAT CARPAL TUNNEL SYNDROME NO SURGICAL INCISION Balloon catheter with bipolar radiofrequency cutting electrode Device inserted into tunnel percutaneously over a guidewire under ultrasound guidance Balloon inflated, stretching the ligament over the ele
Slide 19: Caldus
Caldus MARKET OPPORTUNITY THE PAVMED SOLUTION CLINICAL CALDUS Ablation of pathologic soft tissues Completely disposable tissue ablation devices including for Varicose veins renal denervation Fistulae Direct thermal ablation using proprietary infusion device and Renal denervation for refractory hyper
Slide 20: NextCath
NextCath MARKET OPPORTUNITY THE PAVMED SOLUTION CLINICAL NEXTCATH Short-term catheters Self-anchoring, short-term catheters ADDRESSABLE MARKET Integrated semi-stiff helical portion Total: All short-term vascular catheters ~$1-2B Resists forceful dislodgement while allowing it to be Immediate: Interv
Slide 21: DisappEAR
DisappEAR MARKET OPPORTUNITY ANTIBIOTIC-ELUTING RESORBABLE EAR TUBES CLINICAL REVOLUTIONARY DEVICE TO TREAT PEDIATRIC EAR INFECTIONS Population = Children with persistent ear infections (otitis DISAPPEAR media) or those with middle ear fluid collections (effusions) Antibiotic-eluting ear tube made f
Slide 22: NextFlo
NextFlo MARKET OPPORTUNITY THE PAVMED SOLUTION CLINICAL NEXTFLO Disposable infusion pumps (DIP) Highly accurate DIP using variable flow resistors Increasing numbers receiving infusions outside hospital Resistance varies inversely to driving pressure, maintaining DIPs favored for home infusions becau
Slide 23: Strong expanding intellectual property portfolio
Strong expanding intellectual property portfolio Our proprietary designs, technologies, methods and know-how are of critical importance and we seek to secure patent protection to protect them in the U.S. and throughout the rest of the world Our patent portfolio currently consists of the following: 2
Slide 24: Growth Strategy
Growth Strategy Advance lead products to commercialization quickly and efficiently PortIO, CarpX, NextCath, Caldus, DisappEAR and NextFlo Discussions with large corporate strategics on commercial partnerships Expand product pipeline Ongoing discussions with innovative clinicians and academic medical
Slide 25: Near-and long-term opportunities for value creation
Near-and long-term opportunities for value creation Q4-2018 Caldus Renal Denervation EU/Emerging Market Commercialization DisappEAR Commercialization Q2-2018 Q3-2017 Caldus Renal Denervation CarpX Commercialization CE Mark Submission NextCath Commercialization DisappEAR FDA Submission Q4-2017 Caldus
Slide 26: Equity Securities Overview
26 Equity Securities Overview Market Capitalization Calculation Common Shares Outstanding (21-Nov-2016) 13,310,000 Share Price (21-Nov-2016) $9.20 Market Capitalization $122,452,000 Fully-Diluted Market Capitalization(1) $167,057,243 Warrant Summary Warrants Outstanding (21-Nov-2016) 10,620,295 Warr
Slide 27: Investment Highlights
Investment Highlights Unique, proven business model focused on capital efficiency and speed to market Deep, expanding pipeline of innovative products across a broad spectrum of clinical conditions with clear paths to near-term commercialization Attractive market opportunities for lead products total
Slide 28: Appendix
Appendix 28
Slide 29: Board of Directors with industry and capital markets experience
Board of Directors with industry and capital markets experience LISHANAKLOG, MD MICHAEL GLENNON Chairman, Chief Executive Officer Vice-Chairman RONALD M. Former Healthcare Industry Executive, Avista Capital Partners SPARKS Former Chairman and CEO, Navilyst, Inc. Former President and CEO, Accellent D
Slide 30: Multi-Specialty Medical Advisory Board of renowned physician innovators
Multi-Specialty Medical Advisory Board of renowned physician innovators ALBERT Co-founding Partner and Chief Innovation Officer, CHIN Pavilion MedicalInnovations MD Former Vice President of Research and Chief Innovation Officer,Maquet Cardiovascular/ Guidant Cardiac Surgery Inventor on 184 issued pa
Slide 31: Leadership team's prior track record of success
Leadership team's prior track record of success ANGIOVAC® VENOPAX® HOUDINI® KALEIDOSCOPE Endovascular device to Endoscopic vessel Device to treat chronic Reversible remove large clots and harvest device for total occlusionof inferior vena cavafilter other material coronary bypass peripheral arteries